0.00Open0.00Pre Close0 Volume0 Open Interest410.00Strike Price0.00Turnover0.01%IV-67.05%PremiumDec 20, 2024Expiry Date164.56Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-1.0000Delta0.0000Gamma1.49Leverage Ratio0.0000Theta0.0000Rho-1.49Eff Leverage0.0000Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet